23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Vera Therapeutics, Inc. › 2025-2026

Vera Therapeutics, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Vera Therapeutics, Inc.’s Form 8-K, filed May 26, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 232Asset managers, any item
  • 1,361Fund votes
  • May 21, 2026Meeting date

Results at a glance

Meeting of May 21, 2026: 5 items on Vera Therapeutics, Inc.’s Form 8-K, filed May 26, 2026: 3 elected · 2 approved.

Dissent

Significant dissent: 1 director (23.4% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Vera Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Vera Therapeutics, Inc.

These tallies are Vera Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 26, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Vera Therapeutics, Inc. — official shareholder meeting results, meeting held May 21, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Michael M. Morrisey, Ph.D. 45,288,710---- 13,814,6712,863,469 77%Elected—
Elect Director: Patrick G. Enright 54,697,296---- 4,406,0852,863,469 93%Elected—
Elect Director: James R. Meyers 58,946,269---- 157,1122,863,469 99.7%Elected—
2. Ratification of the Appointment of Independent Registered Public Accounting Firm 61,834,84244,71087,298 ---- 99.9%Approved—
3. Advisory Vote on Executive Compensation 56,585,5682,433,53784,276 --2,863,469 96%Approved—

Source: Vera Therapeutics, Inc., Form 8-K, filed with the SEC on May 26, 2026 — read the filing on EDGAR.

How asset managers voted at the Vera Therapeutics, Inc. 2025-2026 meeting

232 asset managers disclosed a vote on at least one Vera Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: James R. Meyers

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 58,946,269WITHHELD: 157,112
Details: description as filed, official tally, votes by 66 asset managers

Description as filed by funds: To elect the three Class II directors named below to hold office until the Company's 2029 annual meeting of stockholders: James R. Meyers

Vera Therapeutics, Inc.’s own tally for this item (“Elect Director: James R. Meyers”): 58,946,269 for, 157,112 withheld, per its Form 8-K filed May 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the three persons listed below as Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or, if sooner, such director's death, resignation or removal.”
Support: 99.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 17,991,670 for, 25,399 withheld.

FOR
FOR: 17,991,670WITHHOLD: 25,399
Largest asset managers voting on “To elect the three Class II directors named below to hold office until the Company's 2029 annual meeting of st” at Vera Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price3,286,0520 00For
Vanguard3,197,6210 00For
Fidelity2,919,2380 00For
BlackRock2,564,5670 00For
State Street2,031,0760 00For
American Century540,5400 00For
Charles Schwab524,8260 00For
AllianceBernstein434,9930 00For
TIAA424,4930 00For
AB DISCOVERY GROWTH FUND, INC.265,9920 00For
Equitable248,4000 00For
Voya190,7020 00For
Brighthouse110,2460 00For
QUANTITATIVE MASTER SERIES LLC97,7920 00For
AIG/SunAmerica97,3750 00For
Principal96,6960 00For
Dimensional90,8330 00For
Goldman Sachs79,4120 00For
DWS59,5540 00For
ProShares57,7820 00For
Transamerica53,6040 00For
ALPS ETF Trust53,4880 00For
Calamos46,9740 00For
Lincoln Financial43,9080 00For
John Hancock43,0750 00For

Showing the 25 largest of 66 asset managers. All 66 are in the interactive database (link above).

Elect Director: Michael M. Morrisey, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 8 wordings of this item as funds reported it.

77% Majority: yes · of votes cast

FOR 77%WITHHELD
FOR: 45,288,710WITHHELD: 13,814,671
Details: description as filed, official tally, votes by 66 asset managers

Description as filed by funds: To elect the three Class II directors named below to hold office until the Company's 2029 annual meeting of stockholders: Michael M. Morrissey, Ph.D.

Vera Therapeutics, Inc.’s own tally for this item (“Elect Director: Michael M. Morrisey, Ph.D.”): 45,288,710 for, 13,814,671 withheld, per its Form 8-K filed May 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the three persons listed below as Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or, if sooner, such director's death, resignation or removal.”
Support: 77% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 13,706,862 for, 4,285,668 withheld, 24,539 abstained.

FORWITHHOLD
FOR: 13,706,862ABSTAIN: 24,539WITHHOLD: 4,285,668
Largest asset managers voting on “To elect the three Class II directors named below to hold office until the Company's 2029 annual meeting of st” at Vera Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price3,286,0520 00For
Vanguard3,195,1590 232,439For
Fidelity2,919,2380 00For
BlackRock2,564,5670 00For
State Street4,5400 02,026,536Withhold
American Century00 0540,540Withhold
Charles Schwab524,8260 00For
AllianceBernstein00 0434,993Withhold
TIAA424,4930 00For
AB DISCOVERY GROWTH FUND, INC.00 0265,992Withhold
Equitable107,0250 0141,375Mixed
Voya00 0190,702Withhold
Brighthouse90,6260 019,620Mixed
QUANTITATIVE MASTER SERIES LLC97,7920 00For
AIG/SunAmerica00 097,375Withhold
Principal00 096,696Withhold
Dimensional00 090,833Withhold
Goldman Sachs79,4120 00For
DWS00 059,554Withhold
ProShares00 057,782Withhold
Transamerica53,6040 00For
ALPS ETF Trust00 053,488Withhold
Calamos46,9740 00For
Lincoln Financial00 043,908Withhold
John Hancock27,3780 15,6970Mixed

Showing the 25 largest of 66 asset managers. All 66 are in the interactive database (link above).

Elect Director: Patrick G. Enright

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 54,697,296WITHHELD: 4,406,085
Details: description as filed, official tally, votes by 66 asset managers

Description as filed by funds: To elect the three Class II directors named below to hold office until the Company's 2029 annual meeting of stockholders: Patrick G. Enright

Vera Therapeutics, Inc.’s own tally for this item (“Elect Director: Patrick G. Enright”): 54,697,296 for, 4,406,085 withheld, per its Form 8-K filed May 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the three persons listed below as Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or, if sooner, such director's death, resignation or removal.”
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 16,077,761 for, 1,939,301 withheld, 7 abstained.

FOR
FOR: 16,077,761ABSTAIN: 7WITHHOLD: 1,939,301
Largest asset managers voting on “To elect the three Class II directors named below to hold office until the Company's 2029 annual meeting of st” at Vera Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price3,286,0520 00For
Vanguard2,646,2620 7551,352Mixed
Fidelity2,919,2380 00For
BlackRock2,564,5670 00For
State Street2,030,9960 080For
American Century540,5400 00For
Charles Schwab524,8260 00For
AllianceBernstein00 0434,993Withhold
TIAA424,4930 00For
AB DISCOVERY GROWTH FUND, INC.00 0265,992Withhold
Equitable107,0250 0141,375Mixed
Voya00 0190,702Withhold
Brighthouse110,2460 00For
QUANTITATIVE MASTER SERIES LLC97,7920 00For
AIG/SunAmerica97,3750 00For
Principal5,0510 091,645Mixed
Dimensional00 090,833Withhold
Goldman Sachs79,4120 00For
DWS00 059,554Withhold
ProShares57,7820 00For
Transamerica53,6040 00For
ALPS ETF Trust53,4880 00For
Calamos46,9740 00For
Lincoln Financial43,9080 00For
John Hancock43,0750 00For

Showing the 25 largest of 66 asset managers. All 66 are in the interactive database (link above).

Advisory Vote on Executive Compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 56,585,568AGAINST: 2,433,537

Prior year: 96.6% for (May 14, 2025 meeting) ▼ 0.7 pts

Details: description as filed, official tally, votes by 232 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.

Vera Therapeutics, Inc.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 56,585,568 for, 2,433,537 against — passed, per its Form 8-K filed May 26, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on an advisory basis, the compensation awarded to the Company's named executive officers, as disclosed in the Proxy Statement.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 66 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Vera Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price3,286,0520 00For
Vanguard3,197,6192 00For
Fidelity2,919,2380 00For
BlackRock2,564,5670 00For
State Street2,030,212864 00For
American Century0540,540 00Against
Charles Schwab524,8260 00For
AllianceBernstein434,9930 00For
TIAA424,4930 00For
AB DISCOVERY GROWTH FUND, INC.265,9920 00For
Equitable248,4000 00For
Voya190,7020 00For
Brighthouse110,2460 00For
QUANTITATIVE MASTER SERIES LLC97,7920 00For
AIG/SunAmerica97,3750 00For
Principal96,6960 00For
Dimensional90,8330 00For
Goldman Sachs79,4120 00For
DWS59,5540 00For
ProShares57,7820 00For
Transamerica53,6040 00For
ALPS ETF Trust53,4880 00For
Calamos46,9740 00For
Lincoln Financial43,9080 00For
John Hancock43,0750 00For

Fund voting reports, all 66 managers: 17,403,903 for, 587,767 against, 25,399 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 186 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Vera Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Avoro Capital Advisors LLC4,993,0610 00For
T. Rowe Price4,578,7140 00For
Kynam Capital Management, LP00 03,337,893Withhold
State Street3,222,8779,747 00For
Fidelity2,772,5180 00For
Deep Track Capital, LP2,692,6170 00For
DEERFIELD MANAGEMENT COMPANY, L.P.2,055,7970 00For
BlackRock2,010,1795,246 00For
Eversept Partners, LP1,728,4850 00For
GEODE CAPITAL MANAGEMENT, LLC1,563,2710 00For
Sofinnova Investments, Inc.1,440,9420 00For
AllianceBernstein1,257,4000 00For
Vestal Point Capital, LP1,079,2130 00For
PICTET ASSET MANAGEMENT SA957,9360 00For
Point72697,6180 00For
American Century0592,441 00Against
Integral Health Asset Management, LLC589,0810 00For
Charles Schwab530,6780 00For
Rock Springs Capital Management LP503,5850 00For
Vanguard503,4420 00For
Candriam S.C.A.0475,335 00Against
Woodline Partners LP469,7080 00For
Northern Trust438,8236,443 00For
Nuveen437,4930 00For
GREAT POINT PARTNERS LLC398,6960 00For

Institutional-manager reports, all 186 managers: 39,198,030 for, 1,768,203 against, 3,337,893 withheld, 258 abstained, 162 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the Appointment of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

99.9% Approved · of votes cast

FOR 99.9%
FOR: 61,834,842AGAINST: 44,710

Prior year: 100.0% for (May 14, 2025 meeting) ▼ 0.1 pts

Details: description as filed, official tally, votes by 65 asset managers

Description as filed by funds: TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF KPMG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2026.

Vera Therapeutics, Inc.’s own tally for this item (“2. Ratification of the Appointment of Independent Registered Public Accounting Firm”): 61,834,842 for, 44,710 against — passed, per its Form 8-K filed May 26, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 65 asset managers below reported 17,987,631 for, 80 against, 25,399 abstained.

FOR
FOR: 17,987,631AGAINST: 80ABSTAIN: 25,399
Largest asset managers voting on “TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF KPMG LLP AS THE INDEPENDENT REGIST” at Vera Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price3,286,0520 00For
Vanguard3,197,6210 00For
Fidelity2,919,2380 00For
BlackRock2,564,5670 00For
State Street2,030,99680 00For
American Century540,5400 00For
Charles Schwab524,8260 00For
AllianceBernstein434,9930 00For
TIAA424,4930 00For
AB DISCOVERY GROWTH FUND, INC.265,9920 00For
Equitable248,4000 00For
Voya190,7020 00For
Brighthouse110,2460 00For
QUANTITATIVE MASTER SERIES LLC97,7920 00For
AIG/SunAmerica97,3750 00For
Principal96,6960 00For
Dimensional90,8330 00For
Goldman Sachs79,4120 00For
DWS59,5540 00For
ProShares57,7820 00For
Transamerica53,6040 00For
ALPS ETF Trust53,4880 00For
Calamos46,9740 00For
Lincoln Financial43,9080 00For
John Hancock43,0750 00For

Showing the 25 largest of 65 asset managers. All 65 are in the interactive database (link above).

Largest Vera Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 71,782,904 shares outstanding at the time of that meeting.

Fund voting reports: top Vera Therapeutics, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2025-2026
#Asset manager % of shares outstanding
1T. Rowe Price 4.58%
2Vanguard 4.45%
3Fidelity 4.07%
4BlackRock 3.57%
5State Street 2.83%
6American Century 0.75%
7Charles Schwab 0.73%
8AllianceBernstein 0.61%
9TIAA 0.59%
10AB DISCOVERY GROWTH FUND, INC. 0.37%
Institutional-manager reports: top Vera Therapeutics, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2025-2026
#Asset manager % of shares outstanding
1Avoro Capital Advisors LLC 6.96%
2T. Rowe Price 6.38%
3Kynam Capital Management, LP 4.65%
4State Street 4.50%
5Fidelity 3.86%
6Deep Track Capital, LP 3.75%
7DEERFIELD MANAGEMENT COMPANY, L.P. 2.86%
8BlackRock 2.81%
9Eversept Partners, LP 2.41%
10GEODE CAPITAL MANAGEMENT, LLC 2.18%

Reported Vera Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Vera Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock5,088,102 7.09%Form 13F, quarter ended March 31, 2026
T. Rowe Price4,574,030 6.37%Form 13F, quarter ended March 31, 2026
Deep Track Capital, LP3,921,362 5.46%Schedule 13G, filed March 11, 2026
Vanguard Group3,570,401 4.97%Form 13F, quarter ended March 31, 2026
State Street3,363,638 4.69%Form 13F, quarter ended March 31, 2026
Sofinnova Venture Partners X, L.P. ("SVP X")2,793,987 3.89%Schedule 13D, filed March 5, 2026
FMR (Fidelity)2,676,422 3.73%Form 13F, quarter ended March 31, 2026
Geode Capital1,570,077 2.19%Form 13F, quarter ended March 31, 2026
Point721,228,525 1.71%Form 13F, quarter ended March 31, 2026
Goldman Sachs1,133,969 1.58%Form 13F, quarter ended March 31, 2026

Percentages above are of 71,782,904 shares outstanding, as reported by Vera Therapeutics, Inc. on its Form 10-Q dated May 1, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Vera Therapeutics, Inc.'s shareholder meeting held May 21, 2026, in the 2025-2026 proxy season, 232 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,361 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — Vera Therapeutics, Inc.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Vera Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 26, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Vera Therapeutics, Inc.’s 10-Q dated May 1, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Vera Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Vera Therapeutics (VERA) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/vera-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.